| Pharmaceutical Information |
| Drug Name |
Neratinib |
| Drug ID |
BADD_D02489 |
| Description |
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. |
| Indications and Usage |
For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EH02 |
| DrugBank ID |
DB11828
|
| KEGG ID |
D08950
|
| MeSH ID |
C487932
|
| PubChem ID |
9915743
|
| TTD Drug ID |
D0U1ZV
|
| NDC Product Code |
70437-240 |
| UNII |
JJH94R3PWB
|
| Synonyms |
neratinib | N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide | HKI 272 | HKI272 | HKI-272 | neratinib maleate | Nerlynx |
|
| Chemical Information |
| Molecular Formula |
C30H29ClN6O3 |
| CAS Registry Number |
698387-09-6 |
| SMILES |
CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
